Melanotan II research centers on a synthetic cyclic heptapeptide that acts as a non-selective agonist across the melanocortin receptor family, making it one of the most widely studied tool compounds for probing both pigmentation and central nervous system pathways in a single molecule. What distinguishes Melanotan II (MT-II) from more receptor-selective analogs is precisely its breadth: because it engages MC1R, MC3R, MC4R, and MC5R, laboratories use it to interrogate how a shared ligand scaffold produces divergent downstream effects depending on which receptor population and tissue is under investigation. This guide summarizes the receptor pharmacology and the preclinical model systems in which the peptide is examined.
Research Use Only. Melanotan II is supplied strictly for laboratory, in-vitro, and preclinical research use. It is not for human or veterinary use, is not a dietary supplement, and has not been evaluated or approved by the FDA. Nothing here is intended to diagnose, treat, cure, or prevent any disease, and no statement constitutes medical, dosing, or therapeutic guidance.
Structure and Melanocortin Pharmacology
Melanotan II is a cyclic lactam-bridged analog of alpha-melanocyte-stimulating hormone (α-MSH). The core message sequence of native α-MSH — His-Phe-Arg-Trp — is retained, while cyclization through a lactam bridge confers metabolic stability and prolonged receptor engagement relative to the linear parent hormone. This structural rigidity is a key reason MT-II is favored as a research probe: it resists rapid enzymatic degradation that limits the utility of native α-MSH in model systems.
The melanocortin receptors are all Gs-protein-coupled receptors. Agonist binding stimulates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA)-dependent signaling. Because MT-II is non-selective, the biological readout observed in any given experiment is largely a function of receptor distribution:
| Receptor | Principal tissue | Research readout studied |
|---|---|---|
| MC1R | Melanocytes | Eumelanin synthesis, tyrosinase activity, pigmentation |
| MC3R | Hypothalamus, periphery | Energy homeostasis, inflammatory signaling |
| MC4R | CNS (hypothalamus) | Feeding behavior, sexual/arousal circuits, energy balance |
| MC5R | Exocrine glands | Sebaceous and secretory function |
For a deeper treatment of receptor subtypes and signal transduction, see our Melanocortin System: Receptor Mechanism Guide.
Pigmentation Research Models (MC1R)
The most extensively characterized experimental axis for MT-II is MC1R-driven melanogenesis. In cultured melanocyte and melanoma cell lines (such as B16 murine models), research has examined how melanocortin agonism upregulates microphthalmia-associated transcription factor (MITF) and the downstream enzymes tyrosinase, TRP-1, and TRP-2 that govern eumelanin biosynthesis. The cAMP/PKA/CREB cascade is the canonical pathway investigated in these studies.
In vivo, rodent pigmentation models are used to study systemic melanocortin agonism as a way to shift the eumelanin-to-pheomelanin ratio independent of ultraviolet exposure. Researchers frequently pair MT-II with the linear analog Melanotan I (afamelanotide) to contrast a non-selective agonist against a more MC1R-oriented one; the comparative pharmacology is covered in Melanotan I vs II: Melanocortin Comparison.
Behavioral and Central Models (MC4R)
Because MT-II crosses into central melanocortin circuitry, it is a standard tool for studying MC4R-mediated behaviors in preclinical neuroscience. Two research domains dominate:
- Energy balance and feeding. MC4R signaling in the hypothalamus is a critical node in appetite regulation. Studies have examined how central melanocortin agonism suppresses food intake in rodent models, informing understanding of the leptin–POMC–MC4R axis and monogenic obesity phenotypes.
- Arousal and copulatory behavior. A well-documented literature investigates MC4R activation and sexual behavior in male and female rodent models. This line of inquiry ultimately motivated development of the MC4R-focused analog bremelanotide; that receptor-selective story is detailed in our PT-141 Research Guide: Bremelanotide MC4.
The value of MT-II in these paradigms is that it lets investigators establish a melanocortin-dependent phenotype, then dissect it further using selective antagonists (e.g., SHU9119, HS024) or receptor-knockout models to attribute effects to specific subtypes.
Laboratory Handling and Reconstitution
Melanotan II is typically supplied as a sterile lyophilized powder. The following reflects standard laboratory handling for research preparations and is not usage guidance:
- Storage (lyophilized): Store the sealed vial at −20°C, protected from light. The lyophilized form is stable for extended periods under these conditions.
- Reconstitution: Bacteriostatic or sterile water is commonly used to reconstitute research preparations. Introduce the diluent slowly against the vial wall rather than directly onto the peptide pellet, and swirl gently rather than shaking to avoid shear stress.
- Storage (reconstituted): Keep at 2–8°C and use within a limited working window. Avoid repeated freeze–thaw cycles, which promote aggregation and degradation.
- Documentation: Verify identity and purity against the accompanying third-party certificate of analysis (COA) before experimental use.
NeuroLabs supplies Melanotan II 10mg at ≥99% purity, third-party COA-tested, with same-day USA shipping for qualified research settings. An alternative delivery format for certain in-vivo and intranasal absorption studies is discussed in our Melanotan II Nasal Spray: Research Format guide.
Why Non-Selectivity Matters Experimentally
It is tempting to view MT-II's lack of selectivity as a limitation, but in research design it is often the point. A single non-selective agonist provides a broad melanocortin stimulus against which selective ligands and genetic tools can be benchmarked. When an MT-II-induced effect disappears in an MC4R-knockout but persists in an MC1R-knockout, the experiment localizes the phenotype without needing a perfectly selective agonist for every subtype. This "broad agonist plus selective subtraction" strategy is a recurring theme across melanocortin literature and situates MT-II firmly within the broader family of Melanocortin & Reproductive Peptides studied as research tools.
Summary
Melanotan II is a metabolically stabilized, cyclic α-MSH analog whose non-selective agonism across MC1R–MC5R makes it a versatile probe. In pigmentation models it drives the cAMP/MITF/tyrosinase axis; in central models it engages MC4R circuits governing energy balance and copulatory behavior. Its breadth, paired with selective antagonists and knockout systems, allows researchers to map melanocortin biology with precision — all strictly within controlled laboratory research contexts.